Navigation Links
Biodel Inc. to Present at the Canaccord Adams Diabetes and Obesity Conference on June 6th 2008
Date:6/4/2008

DANBURY, Conn., June 4 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Gerard Michel, Chief Financial Officer, Vice President of Corporate Development and Treasurer of Biodel, will present a corporate update at the Canaccord Adams Diabetes and Obesity Conference on Friday, June 6, 2008 at 1:40 p.m. Pacific Daylight Time. The conference will be held at Hotel Nikko in San Francisco.

Interested parties may access a link to a live webcast of the corporate presentation in the investor relations section of Biodel's website at http://www.biodel.com. An archive of the presentation will be available at the same location.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
2. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
3. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
4. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
5. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
6. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
7. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
8. Biodel Inc. Announces Pricing of Public Offering
9. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
10. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
11. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 2Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 3Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 4Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 5Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 6Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 7Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 8Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 9Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 10Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 11Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 12Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 13Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 14Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 15UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 2UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 3UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 4UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 5UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 6Using the OligoGreen Oligonucleotide Quantitation Reagent in the Gemini XS, Gemini EM and SpectraMax M2 Microplate Readers (MaxLine Application Note #21) 2Using the OligoGreen Oligonucleotide Quantitation Reagent in the Gemini XS, Gemini EM and SpectraMax M2 Microplate Readers (MaxLine Application Note #21) 3Using the OligoGreen Oligonucleotide Quantitation Reagent in the Gemini XS, Gemini EM and SpectraMax M2 Microplate Readers (MaxLine Application Note #21) 4